美国食品和药物管理局授予Zymeworks的卵巢癌药物快速通道指定. FDA grants Fast Track designation to Zymeworks' ovarian cancer drug.

美国食品和药物管理局已授予Zymeworks针对晚期卵巢癌的研究药物ZW191快速通道指定. The U.S. Food and Drug Administration has granted Fast Track designation to Zymeworks' investigational drug ZW191 for advanced ovarian cancer. 这种抗体-药物联结剂针对许多卵巢癌中过度表达的蛋白质,并旨在加速其发展. This antibody-drug conjugate targets a protein overexpressed in many ovarian cancers, and the designation aims to accelerate its development. 在宣布此事后,Zymeworks在市场前交易中幅超过3%. Zymeworks stock rose over 3% in premarket trading following the announcement.